On April 14, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 taking place April 17–22 in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The research that Tempus is presenting at this year’s AACR (Free AACR Whitepaper) annual meeting underscores the scale and real-world impact of Tempus’ multimodal dataset and AI-enabled diagnostic solutions," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "Across these studies, our researchers are uncovering clinically relevant insights that not only deepen our understanding of tumor biology, but also have the potential to transform how cancer is diagnosed and treated. This work is a product of our ongoing commitment to advancing the field of oncology and, ultimately, to improving outcomes for the patients we serve."

Tempus will host an Exhibitor Spotlight Theater session on Monday, April 20, 2026, from 10:00–11:00 AM PST in Theater B of the Sails Pavilion. In "Beyond the Pilot: Scaling Multimodal AI and Lab-in-the-Loop for Breakthrough R&D," Sasser and Neil Bence, PhD, Senior Vice President of the Protein Homeostasis Thematic Research Center at Bristol Myers Squibb, will explore how combining deep molecular insights with high-throughput Lab-in-the-Loop functional screening can accelerate breakthroughs.

Tempus research highlights presented at this year’s conference include:

Co-occurrence of gene fusions and microsatellite instability (MSI) defines a clinically distinct subtype of colorectal cancer
Sunday, April 19, 2026, 2:00 – 5:00 PM PT
Section 20
Investigation into the co-occurrence of gene fusions and microsatellite instability (MSI) in 30,884,099 colorectal cancer patients revealed that clinically relevant fusions are significantly enriched in MSI versus MSS tumors (6.2% vs. 2.2%). These findings suggest that the clinical impact of gene fusions is mediated by MSI status, defining a distinct molecular subtype of colorectal cancer that may influence therapeutic stratification.
Oral Presentation: Real-world evidence of KMT2C mutation as a biomarker of sensitivity to platinum-based therapy in solid cancers
Monday, April 20, 2026, 2:30 – 4:30 PM PT
Room 14-Mezzanine Level – Convention Center
Researchers leveraged Tempus Lens to define a real-world cohort of 143,961 patients with solid tumors from the Tempus multimodal database. They sought to determine if KMT2C mutations are a biomarker for sensitivity to platinum-based chemotherapy (PBC). Their analysis revealed that patients with KMT2C mutations had significantly improved real-world overall survival (rwOS) after PBC treatment compared to patients without the mutation (19.6 vs. 16.7 months). The survival benefit was most significant in colorectal cancer (CRC), where patients with the mutation had a median rwOS of 51.0 months versus 25.3 months for those without. These findings, validated in the AACR (Free AACR Whitepaper) Genie dataset, support KMT2C as a predictive biomarker for platinum response—particularly in CRC and GI cancers—with laboratory studies underway to clarify mechanisms.
Analysis of RNA expression of 47 cell surface proteins in real-world small cell lung cancer patients
Tuesday, April 21 9:00 AM – 12:00 PM PT
Section 46
The research team performed an exploratory analysis of 56 cell surface proteins (CSPs) in 1,353 small cell lung cancer (SCLC) patients to identify differential expression patterns across subtypes, disease stages, and treatment statuses. Leveraging Tempus xT DNA-seq and xR RNA-seq data, the study identified subtype-specific expression.
Machine learning predicts retained retinoblastoma (Rb) function in real-world small cell lung cancer patients
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 46
To challenge the long-held belief that the retinoblastoma (RB) tumor suppressor is always inactive in small cell lung cancer (SCLC), the research team developed a machine learning model to predict RB function. Using genomic (Tempus xT) and transcriptomic (Tempus xR) data from a real-world cohort of approximately 1,400 SCLC patients, the model found that nearly 30% of patients with RB1 genomic alterations still showed evidence of RB function transcriptionally.
Immune-related RNA-seq biomarker-based clustering reveals heterogeneous immunotherapy responses and guides subtype-specific strategies in metastatic NSCLC
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 42
Patients with metastatic non-small cell lung cancer (mNSCLC) respond variably to first-line immunotherapy plus chemotherapy, yet the underlying immune biology driving these differences remains poorly understood. In a real-world cohort of 2,235 mNSCLC patients from the Tempus database, RNA-seq-based unsupervised clustering using immune markers identified four biologically distinct immune subtypes.
Validation of HER2, TROP2, and NECTIN4 IHC prediction algorithms for the ADC MATCH trial
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 6
To facilitate patient selection for the ADC MATCH clinical trial, investigators validated RNA-seq algorithms designed to identify patients likely to test positive for HER2, TROP2, and NECTIN4 via immunohistochemistry (IHC).
Detection of rare oncogenic fusions through concurrent DNA and RNA next-generation sequencing in a pan-cancer clinical setting
Wednesday, April 22, 2026, 9:00 AM – 12:00 PM PT
Section 49
By retrospectively analyzing de-identified records from 74,182 patients with advanced cancer, this study quantified the clinical benefit of concurrent DNA and RNA testing for identifying rare oncogenic fusions.
Learn more about Tempus at AACR (Free AACR Whitepaper) Annual Meeting 2026.

(Press release, Tempus, APR 14, 2026, View Source [SID1234664375])